Clinical trials: HIV -1 Infection
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: If taking MK-8527 once a month works to prevent HIV-1 infection better than a…
- Trial name
- NCT07071623
- Testing
- MK-8527, Emtricitabine/tenofovir disoproxil (FTC/TDF)
- Where
- 30 sites in Kenya, South Africa and 1 more
- Volunteers
- 4,580 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 rapid test. The device is intended to qualitatively detect the presence of antibodies against HIV-1/2 in oral fluid…
- Trial name
- NCT01032902
- Testing
- In Vitro Diagnostic Device
- Where
- 5 sites in United States
- Volunteers
- 2,808 people, healthy volunteers welcome
- Sponsor
- Chembio Diagnostic Systems, Inc.
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4004280 in healthy adults.
- Trial name
- NCT05163522
- Testing
- VH4004280, Midazolam
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)
The aim of this study was to determine if virologically suppressed, human immunodeficiency virus type 1 (HIV-1) infected adults on an antiretroviral regimen (including 2 nucleoside reverse transcriptase inhibitors [NRTIs] plus a…
- Trial name
- NCT02422797
- Testing
- DTG 50 mg, RPV 25 mg, CAR
- Where
- 61 sites in United States, Argentina and 9 more
- Volunteers
- 518 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus - Type 1
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
The purpose of this study is to test if being treated with darunavir/ritonavir (DRV/rtv) 800/100 mg daily is as effective as being treated with DRV/rtv 600/100 mg twice daily, in early antiretroviral (ARV)-experienced patients…
- Trial name
- ODIN (NCT00524368)
- Testing
- Darunavir (DRV), Ritonavir (rtv)
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 590 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C Infection With HIV Co-Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02457611
- Testing
- LDV/SOF
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
Hepatitis C, HIV Infections
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV…
- Trial name
- NCT00983853
- Testing
- peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 62 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
HIV Infection
Single DermaVir Immunization in HIV-1 Infected Patients on HAART
DermaVir is a plasmid DNA-containing synthetic nanomedicine. It is administered topically with DermaPrep to target Langerhans cells.
- Trial name
- GIHU004 (NCT00712530)
- Testing
- DermaVir, HAART
- Where
- Hungary
- Volunteers
- 9 people
- Sponsor
- Genetic Immunity
Infection, Human Immunodeficiency Virus I, HIV Infection
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily.
- Trial name
- NCT00082394
- Testing
- Trizivir, atazanavir, Combivir
- Where
- 45 sites in United States, Mexico
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The objective of this study is to evaluate the safety and efficacy of a regimen containing cobicistat-boosted atazanavir (ATV+COBI) plus emtricitabine/tenofovir disoproxil fumarate (Truvada®; FTC/TDF) versus ritonavir-boosted…
- Trial name
- NCT00892437
- Testing
- COBI, RTV, ATV
- Where
- 31 sites in United States
- Volunteers
- 85 people
- Sponsor
- Gilead Sciences
HIV Infections, HIV Seronegativity
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV.
- Trial name
- NCT00002441
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- Where
- 67 sites in United States, Canada and 2 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- VaxGen
Infection, Human Immunodeficiency Virus
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.
- Trial name
- NCT02415595
- Testing
- BMS-955176, EFV, TDF/FTC
- Where
- 64 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus
Prospective Observational Epidemiologic Study of Maraviroc's Safety
The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.
- Trial name
- POEM (NCT00665561)
- Testing
- Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc
- Where
- 269 sites in United States, Belgium and 9 more
- Volunteers
- 2,500 people
- Sponsor
- ViiV Healthcare
HIV Infections
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
This study is to test a therapeutic HIV-1 vaccine (HIVAX™) in HIV-1 infected subjects. The safety and immune responses will be studied in vaccine recipients.
- Trial name
- GCHT01 (NCT01428596)
- Testing
- HIVAX, saline solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GeneCure Biotechnologies
HIV Infections, HIV Seronegativity
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
- Trial name
- NCT00006327
- Testing
- MN rgp120/HIV-1 and A244 rgp120/HIV-1
- Where
- Thailand
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- VaxGen
Human Immunodeficiency Virus Infections
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
The primary purpose of the study is to evaluate the efficacy of rilpivirine (RPV)-based regimen in human immunodeficiency virus type 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive participants, as determined by the…
- Trial name
- RISE (NCT03563742)
- Testing
- Rilpivirine 25 mg, Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)
- Where
- 5 sites in India
- Volunteers
- 58 people
- Sponsor
- Janssen Research & Development, LLC
HIV, Human Immunodeficiency Virus
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy.
- Trial name
- NCT02175680
- Testing
- PRO 140, Historical data
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- CytoDyn, Inc.
AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases
Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
This is a first in human testing of novel HIV-1 protein nanoparticles vaccine candidates, UVAX-1107 and UVAX-1197 mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants.
- Conditions
- AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases, HIV Infections
- Trial name
- NCT06541093
- Testing
- UVAX-1107, UVAX-1197
- Where
- Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Uvax Bio LLC
HIV Infections
Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.
To evaluate the antiretroviral activity and safety of 200 mg BID and 300 mg BID doses of MPC-4326 administered as monotherapy for 14 days to HIV-1 positive patients.
- Trial name
- NCT00967187
- Testing
- bevirimat dimeglumine
- Where
- 4 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Myrexis Inc.
HIV-1-infection
A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings
Participants will be randomized to one of three study vaginal rings (VRs) in a 1:1:1 ratio, 25 mg, 100 mg or 200 mg VRs.
- Trial name
- NCT03234400
- Testing
- Dapivirine Vaginal Ring, 25 mg, Dapivirine Vaginal Ring, 100 mg, Dapivirine Vaginal Ring, 200 mg
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.